Kura Oncology Stock Price, News & Analysis (NASDAQ:KURA) $10.81 -0.49 (-4.34%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$10.40▼$11.4450-Day Range$7.58▼$11.3052-Week Range$7.41▼$15.50Volume1.36 million shsAverage Volume685,951 shsMarket Capitalization$802.86 millionP/E RatioN/ADividend YieldN/APrice Target$27.31 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Kura Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside152.7% Upside$27.31 Price TargetShort InterestBearish16.52% of Float Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment-0.08Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.09) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.66 out of 5 starsMedical Sector849th out of 954 stocksBiotechnology Industry94th out of 111 stocks 3.4 Analyst's Opinion Consensus RatingKura Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.31, Kura Oncology has a forecasted upside of 152.7% from its current price of $10.81.Amount of Analyst CoverageKura Oncology has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.52% of the float of Kura Oncology has been sold short.Short Interest Ratio / Days to CoverKura Oncology has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in Kura Oncology has recently increased by 7.62%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKura Oncology does not currently pay a dividend.Dividend GrowthKura Oncology does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKura Oncology has received a 73.98% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kura Oncology is -0.76. Previous Next 1.6 News and Social Media Coverage News SentimentKura Oncology has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Kura Oncology this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for KURA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows3 people have added Kura Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kura Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of Kura Oncology is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kura Oncology are expected to decrease in the coming year, from ($2.09) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kura Oncology is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kura Oncology is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKura Oncology has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kura Oncology Stock (NASDAQ:KURA)Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.Read More KURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KURA Stock News HeadlinesDecember 9, 2023 | americanbankingnews.comKura Oncology (NASDAQ:KURA) Given "Buy" Rating at HC WainwrightDecember 8, 2023 | stockhouse.comKura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical TrialDecember 9, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 28, 2023 | finance.yahoo.comKura Oncology to Participate in the JMP Securities Hematology and Oncology SummitNovember 5, 2023 | finance.yahoo.comKura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Call TranscriptNovember 5, 2023 | benzinga.comKura Oncology Stock (NASDAQ:KURA), Analyst Ratings, Price Targets, PredictionsNovember 4, 2023 | markets.businessinsider.comScotiabank Reaffirms Their Hold Rating on Kura Oncology (KURA)November 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Penumbra (PEN), Butterfly Network (BFLY) and Kura Oncology (KURA)December 9, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 3, 2023 | msn.comKura Oncology files for $150M common stock offering, mixed securities shelfNovember 3, 2023 | msn.comKura Oncology GAAP EPS of -$0.50 beats by $0.05November 2, 2023 | seekingalpha.comKura Oncology, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 2, 2023 | finance.yahoo.comKura Oncology Inc (KURA) Reports Q3 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comKura Oncology Reports Third Quarter 2023 Financial ResultsOctober 30, 2023 | finance.yahoo.comKura Oncology to Participate in Three Upcoming Investor ConferencesOctober 26, 2023 | finance.yahoo.comKura Oncology to Report Third Quarter 2023 Financial ResultsOctober 20, 2023 | markets.businessinsider.comPromising Clinical Trials and Underappreciated FTI Pipeline Justify Buy Rating for Kura OncologyOctober 19, 2023 | msn.comWedbush Reiterates Kura Oncology (KURA) Outperform RecommendationOctober 19, 2023 | stockhouse.comKura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806October 19, 2023 | finance.yahoo.comKura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806October 18, 2023 | msn.comKura aims FDA approval with positive data for tipifarnib in pivotal trialOctober 18, 2023 | finanznachrichten.deKura Oncology, Inc.: Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCCOctober 17, 2023 | finance.yahoo.comKura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCCOctober 9, 2023 | finance.yahoo.com14 Best Cancer Stocks To Buy NowOctober 4, 2023 | finance.yahoo.comWhat Makes Kura Oncology (KURA) a New Buy StockOctober 4, 2023 | finance.yahoo.comKura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 3, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Lantheus (LNTH), Kura Oncology (KURA)See More Headlines Receive KURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KURA CUSIPN/A CIK1422143 Webwww.kuraoncology.com Phone(858) 500-8800FaxN/AEmployees131Year FoundedN/APrice Target and Rating Average Stock Price Target$27.31 High Stock Price Target$37.00 Low Stock Price Target$10.50 Potential Upside/Downside+152.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.54% Return on Assets-30.90% Debt Debt-to-Equity Ratio0.02 Current Ratio16.71 Quick Ratio16.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.28 per share Price / Book1.72Miscellaneous Outstanding Shares74,272,000Free Float70,113,000Market Cap$802.88 million OptionableOptionable Beta0.68 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesTroy E. WilsonChairman, President, CEO & Chief Financial OfficerKathleen FordChief Operating OfficerStephen DaleChief Medical OfficerMollie LeoniSenior Vice President-Clinical DevelopmentBrian T. PowlChief Commercial OfficerKey CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTSana BiotechnologyNASDAQ:SANAEditas MedicineNASDAQ:EDITZymeworksNYSE:ZYME4D Molecular TherapeuticsNASDAQ:FDMTView All CompetitorsInsiders & InstitutionsCitigroup Inc.Bought 22,357 shares on 12/6/2023Ownership: 0.133%American Century Companies Inc.Bought 12,791 shares on 11/30/2023Ownership: 0.065%Deutsche Bank AGBought 4,539 shares on 11/24/2023Ownership: 0.043%Graham Capital Management L.P.Sold 9,487 shares on 11/22/2023Ownership: 0.028%Walleye Capital LLCBought 182,221 shares on 11/21/2023Ownership: 0.357%View All Insider TransactionsView All Institutional Transactions KURA Stock Analysis - Frequently Asked Questions Should I buy or sell Kura Oncology stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KURA shares. View KURA analyst ratings or view top-rated stocks. What is Kura Oncology's stock price target for 2024? 8 Wall Street research analysts have issued 1-year price targets for Kura Oncology's shares. Their KURA share price targets range from $10.50 to $37.00. On average, they predict the company's share price to reach $27.31 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price. View analysts price targets for KURA or view top-rated stocks among Wall Street analysts. How have KURA shares performed in 2023? Kura Oncology's stock was trading at $12.41 on January 1st, 2023. Since then, KURA shares have decreased by 12.9% and is now trading at $10.81. View the best growth stocks for 2023 here. When is Kura Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our KURA earnings forecast. How were Kura Oncology's earnings last quarter? Kura Oncology, Inc. (NASDAQ:KURA) released its earnings results on Thursday, November, 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.06. What ETF holds Kura Oncology's stock ? Simplify Propel Opportunities ETF holds 80,000 shares of KURA stock, representing 0.79% of its portfolio. What other stocks do shareholders of Kura Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD). Who are Kura Oncology's major shareholders? Kura Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Deerfield Management Company L.P. Series C (5.89%), Armistice Capital LLC (3.01%), Affinity Asset Advisors LLC (1.15%), Northern Trust Corp (0.95%), Acuta Capital Partners LLC (0.95%) and Charles Schwab Investment Management Inc. (0.76%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Thomas James Doyle and Thomas Malley. View institutional ownership trends. How do I buy shares of Kura Oncology? Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:KURA) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.